98%
921
2 minutes
20
Although glycogen synthase kinase β (Gsk3β) has been shown to regulate tissue inflammation, whether and how it regulates inflammation resolution versus inflammation activation is unclear. In a murine liver, partial warm ischemia/reperfusion injury (IRI) model, we found that Gsk3β inhibitory phosphorylation increased at both the early-activation and late-resolution stages of the disease. Myeloid Gsk3β deficiency not only alleviated liver injuries, it also facilitated the restoration of liver homeostasis. Depletion of Kupffer cells prior to the onset of liver ischemia diminished the differences between the WT and Gsk3β-KO mice in the activation of liver IRI. However, the resolution of liver IRI remained accelerated in Gsk3β-KO mice. In CD11b-DTR mice, Gsk3β-deficient BM-derived macrophages (BMMs) facilitated the resolution of liver IRI as compared with WT cells. Furthermore, Gsk3β deficiency promoted the reparative phenotype differentiation in vivo in liver-infiltrating macrophages and in vitro in BMMs. Gsk3 pharmacological inhibition promoted the resolution of liver IRI in WT, but not myeloid MerTK-deficient, mice. Thus, Gsk3β regulates liver IRI at both activation and resolution stages of the disease. Gsk3 inactivation enhances the proresolving function of liver-infiltrating macrophages in an MerTK-dependent manner.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870084 | PMC |
http://dx.doi.org/10.1172/jci.insight.151819 | DOI Listing |
J Fish Biol
September 2025
Department of Marine Renewable Resources, Institute of Marine Science, Barcelona, Spain.
This study investigates whether size-selective harvesting induced heritable changes reflected in epigenetic and reproductive molecular markers in zebrafish (Danio rerio), thereby indicating potential evolutionary responses. We used an experimental harvest model where zebrafish populations were subjected to five generations of size-selective harvesting, followed by eight generations without harvesting in a controlled environment to examine evolutionarily fixed outcomes in response to harvest selection. We assumed the evolutionary adaptations to size-selection to have left a molecular legacy related to sexual development, as previous studies have shown that evolution of reproductive timing is a common response to size-selection.
View Article and Find Full Text PDFSemin Cancer Biol
September 2025
Department of Oncology, Olomouc University Hospital, Olomouc, Czech Republic. Electronic address:
FOLFIRINOX and gemcitabine plus nab-paclitaxel represent the most effective chemotherapy regimens for metastatic pancreatic cancer patients nowadays, but the median overall survival remains less than one year. Pharmacogenomics and the individualization of therapy represent a promising strategy, including identifying patients at increased risk of toxicity. This review summarizes contemporary knowledge about genetic variability and putative biomarkers with published associations to therapy responses of pancreatic cancer not only for gold standard treatment regimens (FOLFIRINOX, gemcitabine/nab-paclitaxel and nal-IRI/5-fluorouracil) but also for other therapeutic options regarding targeted therapy and immunotherapy.
View Article and Find Full Text PDFHum Immunol
September 2025
MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA. Electronic address:
Current approaches used for pediatric liver transplant (LT) surveillance have diagnostic limitations. We used pleximmune™ immune reactivity index (IRI) and anti-HLA donor specific antibody (DSA) to predict the adequacy of immunosuppression (IS) relative to risk of acute cellular rejection (ACR) at 1-year post LT. This is a retrospective chart review of children who underwent LT between January 1, 2016, through December 31, 2020, and had at least one pleximmune measurement performed within 60-days of a liver biopsy.
View Article and Find Full Text PDFHepatobiliary Surg Nutr
August 2025
Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Background And Objective: Hemadsorption, a therapeutic modality traditionally used to mitigate cytokine storm in critically ill patients and is now being tested in other medical fields including organ transplantation, especially for organs from extended criteria donors. Such organs are susceptible to ischemia-reperfusion injury (IRI) during transplantation, which is known to release a cascade of innate immune mediators including damage-associated molecular patterns (DAMPs) and cytokines during reperfusion and ultimately leading to graft dysfunction based on the metabolic injury. To address this challenge, early studies have integrated hemadsorption filters into organ perfusion circuits, such as normothermic regional perfusion (NRP) in donors and machine perfusion (MP) of grafts, with the aim to reduce inflammation and improve organ viability.
View Article and Find Full Text PDFMater Today Bio
October 2025
Institute for Engineering Medicine, Kunming Medical University, Kunming, 650500, China.
Hepatic ischemia-reperfusion injury (IRI) poses a significant clinical challenge in liver surgery and transplantation, primarily mediated through oxidative stress, mitochondrial dysfunction, and inflammatory activation. Herein, we developed SOD2-Res@CVs, an engineered vesicular platform combining SOD2-overexpressing mesenchymal stem cell-derived vesicles with liver-targeted and ROS-responsive resveratrol (Res)-loaded liposomes for multi-mechanistic intervention. In vivo imaging demonstrated that SOD2-Res@CVs selectively accumulated in IRI-damaged hepatic tissues.
View Article and Find Full Text PDF